The DOI matches its Crossref record; 70 of the 71 references it cites were found in a registry or an index.
Antisense Oligonucleotide Inhibition of Apolipoprotein C-III Reduces Plasma Triglycerides in Rodents, Nonhuman Primates, and Humans
Abstract
Rationale: Elevated plasma triglyceride levels have been recognized as a risk factor for the development of coronary heart disease. Apolipoprotein C-III (apoC-III) represents both an independent risk factor and a key regulatory factor of plasma triglyceride concentrations. Furthermore, elevated apoC-III levels have been associated with metabolic syndrome and type 2 diabetes mellitus. To date, no selective apoC-III therapeutic agent has been evaluated in the clinic. Objective: To test the hypothesis that selective inhibition of apoC-III with antisense drugs in preclinical models and in healthy volunteers would reduce plasma apoC-III and triglyceride levels. Methods and Results: Rodent- and human-specific second-generation antisense oligonucleotides were identified and evaluated in preclinical models, including rats, mice, human apoC-III transgenic mice, and nonhuman primates. We demonstrated the selective reduction of both apoC-III and triglyceride in all preclinical pharmacological evaluations. We also showed that inhibition of apoC-III was well tolerated and not associated with increased liver triglyceride deposition or hepatotoxicity. A double-blind, placebo-controlled, phase I clinical study was performed in healthy subjects. Administration of the human apoC-III antisense drug resulted in dose-dependent reductions in plasma apoC-III, concomitant lowering of triglyceride levels, and produced no clinically meaningful signals in the safety evaluations. Conclusions: Antisense inhibition of apoC-III in preclinical models and in a phase I clinical trial with healthy subjects produced potent, selective reductions in plasma apoC-III and triglyceride, 2 known risk factors for cardiovascular disease. This compelling pharmacological profile supports further clinical investigations in hypertriglyceridemic subjects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The data remain inconclusive and the clinical efficacy of omega-3 fatty acids appears to be related to non-lipid effects [330,331].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [330]
In the citing paper
“ApoCIII has been identified as a new potential therapeutic target that is currently being studied, but whether it has a role in clinical practice is unknown and its measurements on a routine basis are not encouraged. 108”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [108]
In the citing paper
“ApoCIII has been identified as a new potential therapeutic target that is currently being studied, but whether it has a role in clinical practice is unknown and its measurements on a routine basis are not encouraged.108”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [108]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Circulation · doi:10.1161/01.cir.0000133317.49796.0e · Cited by 6,902
Ethical principles for medical research involving human subjects
Eckstein, S. (2003) · Cambridge University Press eBooks · doi:10.1017/cbo9780511550089.027 · Cited by 2,592
Available, N. (2000) · JAMA · doi:10.1001/jama.284.23.3043 · Cited by 2,344
Triglycerides and Cardiovascular Disease: A Scientific Statement From the American Heart Association
Miller, M., Stone, N. J., Ballantyne, C., Bittner, V., Criqui, M. H., Ginsberg, H. N., Goldberg, A. C., Howard, W. J., Jacobson, M. S., Kris-Etherton, P. M., et al. (2011) · Circulation · doi:10.1161/cir.0b013e3182160726 · Cited by 1,871
Sarwar, N., Danesh, J., Eiriksdottir, G., Sigurdsson, G., Wareham, N., Bingham, S., Boekholdt, S. M., Khaw, K.-T., & Gudnason, V. (2007) · Circulation · doi:10.1161/circulationaha.106.637793 · Cited by 1,408
Lipoprotein lipase: from gene to obesity
Wang, H., & Eckel, R. H. (2009) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.90920.2008 · Cited by 741
Pollin, T. I., Damcott, C. M., Shen, H., Ott, S. H., Shelton, J., Horenstein, R. B., Post, W., McLenithan, J. C., Bielak, L. F., Peyser, P. A., et al. (2008) · Science · doi:10.1126/science.1161524 · Cited by 688
Carr, T. P., Andresen, C. J., & Rudel, L. L. (1993) · Clinical Biochemistry · doi:10.1016/0009-9120(93)90015-x · Cited by 558
Sacks, F. M., Alaupovic, P., Moye, L. A., Cole, T. G., Sussex, B., Stampfer, M. J., Pfeffer, M. A., & Braunwald, E. (2000) · Circulation · doi:10.1161/01.cir.102.16.1886 · Cited by 490
Excess of rare variants in genes identified by genome-wide association study of hypertriglyceridemia
Johansen, C. T., Wang, J., Lanktree, M. B., Cao, H., McIntyre, A. D., Ban, M. R., Martins, R. A., Kennedy, B. A., Hassell, R. G., Visser, M. E., et al. (2010) · Nature Genetics · doi:10.1038/ng.628 · Cited by 437
Flagged first, then by citations
1 of the 71 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- 10.1194/jlr.M900346-JLR200 · DOI
Cited by
Sorted by citations
Items 201–300 of 377
APOC3 Protein Is Not a Predisposing Factor for Fat-induced Nonalcoholic Fatty Liver Disease in Mice
Cheng, X., Yamauchi, J., Lee, S., Zhang, T., Gong, Z., Muzumdar, R. H., Qu, S., & Dong, H. H. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.765917 · Cited by 21
Apolipoprotein CIII and diabetes. Is there a link?
Christopoulou, E. C., Tsimihodimos, V., Filippatos, T. D., & Elisaf, M. (2018) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3118 · Cited by 21
Activity of nucleic acid polymers in rodent models of HBV infection
Schöneweis, K., Motter, N. E., Roppert, P. L., Lu, M., Wang, B., Roehl, I., Glebe, D., Yang, D., Morrey, J. D., Roggendorf, M., et al. (2017) · Antiviral Research · doi:10.1016/j.antiviral.2017.10.022 · Cited by 20
New and Emerging Biomarkers in Cardiovascular Disease
Cahill, L. E., Bertoia, M. L., Aroner, S. A., Mukamal, K. J., & Jensen, M. K. (2015) · Current Diabetes Reports · doi:10.1007/s11892-015-0661-y · Cited by 20
Yao, Z., Zhang, L. R., & Ji, G. (2014) · Journal of Chinese Integrative Medicine · doi:10.1016/s2095-4964(14)60023-6 · Cited by 19
Impaired postprandial lipemic response in chronic kidney disease
Saland, J. M., Satlin, L. M., Zalsos-Johnson, J., Cremers, S., & Ginsberg, H. N. (2016) · Kidney International · doi:10.1016/j.kint.2016.02.031 · Cited by 19
Gene-based therapies in lipidology
Gaudet, D., & Brisson, D. (2015) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000240 · Cited by 20
Apoprotein C-III: A review of its clinical implications
Jin, J., Guo, Y., & Li, J. (2016) · Clinica Chimica Acta · doi:10.1016/j.cca.2016.06.016 · Cited by 21
Triglyceride-Rich Lipoproteins and Novel Targets for Anti-atherosclerotic Therapy
Reiner, Ž. (2018) · Korean Circulation Journal · doi:10.4070/kcj.2018.0343 · Cited by 19
Jansen, H., Lieb, W., & Schunkert, H. (2016) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-016-6640-y · Cited by 19
Lowering apolipoprotein CIII protects against high-fat diet–induced metabolic derangements
Valladolid‐Acebes, I., Åvall, K., Recio-López, P., Moruzzi, N., Bryzgalova, G., Björnholm, M., Krook, A., Fauste, E., Ericsson, M., Landfors, F., et al. (2021) · Science Advances · doi:10.1126/sciadv.abc2931 · Cited by 18
Soto, L. G. D. L. P., Gutierrez-Uribe, J. A., Sharma, A. K., & Ramírez‐Jiménez, A. K. (2021) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2021.09.035 · Cited by 19
Karwatowska‐Prokopczuk, E., Lesogor, A., Yan, J., Hoenlinger, A., Margolskee, A., Li, L., & Tsimikas, S. (2024) · Lipids in Health and Disease · doi:10.1186/s12944-024-02297-5 · Cited by 19
Nedelkov, D. (2017) · Proteomes · doi:10.3390/proteomes5040027 · Cited by 16
A Tale of Two New Targets for Hypertriglyceridaemia: Which Choice of Therapy?
Ward, N. C., Chan, D. C., & Watts, G. F. (2022) · BioDrugs · doi:10.1007/s40259-022-00520-2 · Cited by 18
Recent Advances in Medicinal Chemistry of Antisense Oligonucleotides
Ito, K. R., & Obika, S. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.12420-5 · Cited by 19
Feingold, K. R. (2017) · Europe PMC (PubMed Central) · Cited by 18
Renal Safety Assessment of Lipid-Lowering Drugs: Between Old Certainties and New Questions
Tramontano, D., Bini, S., Maiorca, C., Di Costanzo, A., Carosi, M., Castellese, J., Arizaj, I., Commodari, D., Covino, S., Sansone, G., et al. (2025) · Drugs · doi:10.1007/s40265-025-02158-0 · Cited by 17
Salakhutdinov, N. F., & Laev, S. S. (2014) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2014.05.008 · Cited by 17
Development of Antisense Drugs for Dyslipidemia
Yamamoto, T., Wada, F., & Harada‐Shiba, M. (2016) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv16001 · Cited by 17
Milonas, D., & Τζιόμαλος, Κ. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1582028 · Cited by 17
An overview of persistent chylomicronemia: much more than meets the eye
Larouche, M., Watts, G. F., Ballantyne, C. M., & Gaudet, D. (2025) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000903 · Cited by 17
Human proteoforms as new targets for clinical mass spectrometry protein tests
Nedelkov, D. (2017) · Expert Review of Proteomics · doi:10.1080/14789450.2017.1362337 · Cited by 16
Zhou, X., Wang, S., Zhu, Y., Pan, Y., Zhang, L., & Yang, Z. (2019) · Medicinal Research Reviews · doi:10.1002/med.21652 · Cited by 18
Shetty, S. K., Walzem, R. L., & Davies, B. S. J. (2020) · Journal of Lipid Research · doi:10.1194/jlr.d119000388 · Cited by 18
Katzmann, J. L., Werner, C. M., Stojaković, T., März, W., Scharnagl, H., & Laufs, U. (2020) · Lipids in Health and Disease · doi:10.1186/s12944-020-01293-9 · Cited by 16
Silbernagel, G., Scharnagl, H., Kleber, M. E., Hoffmann, M. M., Delgado, G., Stojaković, T., Gary, T., Zeng, L., Ritsch, A., Zewinger, S., et al. (2020) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2020.08.017 · Cited by 16
Rajan, S., de Guzman, H. C., Palaia, T. A., Goldberg, I. J., & Hussain, M. M. (2021) · Journal of Lipid Research · doi:10.1016/j.jlr.2021.100115 · Cited by 17
New Aspects of Gene-Silencing for the Treatment of Cardiovascular Diseases
Koenig, O., Walker, T., Perle, N., Zech, A., Neumann, B., Schlensak, C., Wendel, H.-P., & Nolte, A. (2013) · Pharmaceuticals · doi:10.3390/ph6070881 · Cited by 15
Hiraoka, H., Shu, Z., Le, B. T., Masuda, K., Nakamoto, K., Lyu, F., Abe, N., Hashiya, F., Kimura, Y., Shimizu, Y., et al. (2021) · ChemBioChem · doi:10.1002/cbic.202100413 · Cited by 15
Sun, M., Chen, L., Liu, H., Ma, L., Wang, T., & Liu, Y. (2017) · Lipids in Health and Disease · doi:10.1186/s12944-017-0614-3 · Cited by 14
Reversal of hypertriglyceridemia in diabetic BTBR ob/ob mice does not prevent nephropathy
Attie, A., Schueler, K., Keller, M. P., Mitok, K. A., Simonett, S. P., Hudkins, K. L., Mehrotra, K., Graham, M. J., Lee, R. G., & Alpers, C. E. (2021) · Laboratory Investigation · doi:10.1038/s41374-021-00592-8 · Cited by 14
Self-citationRecent Apolipoprotein CIII trials
Tramontano, D., Bini, S., D’Erasmo, L., & Arca, M. (2022) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000849 · Cited by 14
The Ebbs and Flows in the Development of Cholesterol-Lowering Drugs: Prospects for the Future
Hajhosseiny, R., Sabir, I. N., Khavandi, K., & Wierzbicki, A. S. (2014) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2014.76 · Cited by 13
Inhibition of Angiopoietin-Like Protein 3 or 3/8 Complex and ApoC-III in Severe Hypertriglyceridemia
Larouche, M., Khoury, É., Brisson, D., & Gaudet, D. (2023) · Current Atherosclerosis Reports · doi:10.1007/s11883-023-01179-y · Cited by 14
Yu, Q., Liu, Z., Waqar, A. B., Ning, B., Yang, X., Shiomi, M., Graham, M. J., Crooke, R. M., Liu, E., Dong, S., et al. (2014) · Mediators of Inflammation · doi:10.1155/2014/979132 · Cited by 14
Self-citationTsimikas, S., Ginsberg, H. N., Alexander, V. J., Karwatowska‐Prokopczuk, E., Dibble, A., Li, L., Witztum, J. L., & Hegele, R. A. (2024) · Journal of clinical lipidology · doi:10.1016/j.jacl.2024.12.018 · Cited by 12
Self-citationNovel Therapeutics for Familial Chylomicronemia Syndrome
Izar, M. C. D. O., & Fonseca, F. A. H. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01295-x · Cited by 13
Evolving targets for lipid‐modifying therapy
Do, R. Q., Nicholls, S. J., & Schwartz, G. G. (2014) · EMBO Molecular Medicine · doi:10.15252/emmm.201404000 · Cited by 13
Afanasieva, O. I., Владиславович, Е. М., & Pokrovsky, S. N. (2018) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2018-8-99-109 · Cited by 15
Cervantes, J., Koška, J., Kramer, F., Akilesh, S., Alpers, C. E., Mullick, A. E., Reaven, P. D., & Kanter, J. E. (2024) · JCI Insight · doi:10.1172/jci.insight.177268 · Cited by 13
Self-citationA significant presence in atherosclerotic cardiovascular disease: Remnant cholesterol: A review
Wang, L., Zhang, Q., Wu, Z., & Huang, X. (2024) · Medicine · doi:10.1097/md.0000000000038754 · Cited by 13
Yamamoto, T., Obika, S., Nakatani, M., Yasuhara, H., Wada, F., Shibata, E., Shibata, M., & Harada‐Shiba, M. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.11.004 · Cited by 11
Looking into the Crystal Ball—Upcoming Drugs for Dyslipidemia
George, M., Selvarajan, S., Rajaram, M., & Shanmugam, E. (2014) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248414545127 · Cited by 11
Apolipoproteins A-I, B, and C-III and Obesity in Young Adult Cherokee
Wang, W., Blackett, P. R., Khan, S. H., & Lee, E. T. (2017) · Journal of Lipids · doi:10.1155/2017/8236325 · Cited by 11
An evidence map of randomised controlled trials evaluating genetic therapies
Apaydin, E. A., Richardson, A. S., Baxi, S. M., Vockley, J., Akinniranye, O., Ross, R., Larkin, J., Motala, A., Azhar, G. S., & Hempel, S. (2020) · BMJ Evidence-Based Medicine · doi:10.1136/bmjebm-2020-111448 · Cited by 11
Prospect and progress of gene therapy in treating atherosclerosis
Kivelä, A. M., Huusko, J., & Ylä‐Herttuala, S. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2015.1084282 · Cited by 11
LDL, HDL, VLDL, and CVD Prevention: Lessons from Genetics?
Hewing, B., & Landmesser, U. (2015) · Current Cardiology Reports · doi:10.1007/s11886-015-0610-z · Cited by 11
New and Future Parenteral Therapies for the Management of Lipid Disorders
García, R. R., & Burkle, J. (2018) · Archives of Medical Research · doi:10.1016/j.arcmed.2019.01.001 · Cited by 10
Development of Antisense Oligonucleotide Gapmers for the Treatment of Dyslipidemia and Lipodystrophy
Aslesh, T., & Yokota, T. (2020) · Methods in molecular biology · doi:10.1007/978-1-0716-0771-8_5 · Cited by 10
New Therapies for Coronary Artery Disease: Genetics Provides a Blueprint
Rader, D. J. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008535 · Cited by 10
Bellosta, S., Rossi, C., Alieva, A. S., Catapano, A. L., Corsini, A., & Baragetti, A. (2023) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-021-07293-w · Cited by 10
Antisense RNA Therapeutics: A Brief Overview
Arechavala‐Gomeza, V., & Garanto, A. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-2010-6_2 · Cited by 10
Antisense Oligonucleotides, microRNAs, and Antibodies
Dávalos, A., & Chroni, A. (2014) · Handbook of experimental pharmacology · doi:10.1007/978-3-319-09665-0_22 · Cited by 10
A New Modality in Dyslipidemia Treatment: Antisense Oligonucleotide Therapy
Kim, K., & Choi, S. H. (2022) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2022.11.3.250 · Cited by 11
Contemporary and Novel Therapeutic Options for Hypertriglyceridemia
Bell, D. A., & Watts, G. F. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.08.001 · Cited by 9
Insights from population-based analyses of plasma lipids across the allele frequency spectrum
Peloso, G. M., & Natarajan, P. (2018) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2018.01.003 · Cited by 10
PIRIE, E. C., Ray, S., Pan, C., Fu, W., Powers, A. F., Polikoff, D., Miller, C. M., Kudrna, K. M., Harris, E. N., Lusis, A. J., et al. (2018) · PLoS Genetics · doi:10.1371/journal.pgen.1007732 · Cited by 9
Self-citationTherapeutic inhibition of apoC-III for the treatment of hypertriglyceridemia
Bell, T. A., Graham, M. J., Baker, B. F., & Crooke, R. M. (2015) · Clinical Lipidology · doi:10.2217/clp.15.7 · Cited by 9
Self-citationBiotechnology Approaches for the Treatment of Dyslipidemia
Parolini, C. (2020) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-020-07017-6 · Cited by 10
Genetics of remnant cholesterol
Wulff, A. B., & Nordestgaard, B. G. (2025) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000991 · Cited by 8
ApoC-III as Therapeutic Target: Is it Primetime for Clinical Use?
Biolo, M., Galimberti, F., Portinari, C., Bertocco, S., Tosin, P., Casula, M., Previato, L., Zambon, S., Simioni, P., & Zambon, A. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01315-w · Cited by 9
Sinning, D., Leistner, D. M., & Landmesser, U. (2016) · Herz · doi:10.1007/s00059-016-4430-8 · Cited by 9
Templated DNA Cross‐Linking: Towards a Non‐Invasive Singlet‐Oxygen‐Based Triggering Method
Laet, N. D., Llamas, E. M., & Madder, A. (2018) · ChemPhotoChem · doi:10.1002/cptc.201700175 · Cited by 8
Recio-López, P., Valladolid‐Acebes, I., Berggren, P., & Juntti‐Berggren, L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms23010062 · Cited by 8
Experimental Biology for the Identification of Causal Pathways in Atherosclerosis
Guo, Y., Garcia-Barrio, M. T., Wang, L., & Chen, Y. (2016) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-016-6644-7 · Cited by 8
Baker, B. F., Xia, S., Partridge, W., Engelhardt, J. A., Tsimikas, S., Crooke, S. T., Bhanot, S., & Geary, R. S. (2024) · Nucleic Acid Therapeutics · doi:10.1089/nat.2023.0026 · Cited by 8
Self-citationPackard, C. J., Taskinen, M., Björnson, E., Matikainen, N., Söderlund, S., Andersson, L. K., Adiels, M., & Borén, J. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.119166 · Cited by 7
The past, present and future of lipidlowering therapy
Najam, O., Lambert, G. C., & Ray, K. K. (2015) · Clinical Lipidology · doi:10.2217/clp.15.40 · Cited by 7
Gene Delivery in Lipid Research and Therapies
Giorgi, M. D., & Lagor, W. R. (2019) · Methodist DeBakey Cardiovascular Journal · doi:10.14797/mdcj-15-1-62 · Cited by 7
Sample Preparation for LC‐MS Bioanalysis of Oligonucleotides
Bartlett, M. G., Kim, J., Basiri, B., & Li, N. (2019) · Wiley eBooks · doi:10.1002/9781119274315.ch25 · Cited by 7
Peng, X., Lian, Z., O’Brien, V., Xiao, J., Litchfield, B., Perrard, X. D., Lu, X., Ni, J., Mukherjee, A., Simmons, T., et al. (2025) · Journal of Lipid Research · doi:10.1016/j.jlr.2025.100763 · Cited by 7
Self-citationOngoing challenges for pharmacotherapy for dyslipidemia
Pisaniello, A. D., Scherer, D. J., Kataoka, Y., & Nicholls, S. J. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.986094 · Cited by 6
Life is complicated: so is apoCIII
Reyes‐Soffer, G., & Ginsberg, H. N. (2019) · Journal of Lipid Research · doi:10.1194/jlr.c119000214 · Cited by 6
Treatment of the metabolic syndrome by siRNA targeting apolipoprotein CIII
Recio-López, P., Valladolid‐Acebes, I., Hadwiger, P., Hoßbach, M., Krampert, M., Prata, C. A. H., Berggren, P., & Juntti‐Berggren, L. (2022) · BioFactors · doi:10.1002/biof.1885 · Cited by 6
Kim, D. H., Lee, S., Noh, S. G., Lee, J., & Chung, H. Y. (2024) · Aging · doi:10.18632/aging.205610 · Cited by 6
Saleh, A. F. A., Priestley, C. C., Gooderham, N. J., & Fellows, M. D. (2015) · Toxicological Sciences · doi:10.1093/toxsci/kfv043 · Cited by 6
Emerging Therapeutic Approaches to Treat Dyslipidemia
Preiss, D., & Packard, C. J. (2014) · Current Cardiology Reports · doi:10.1007/s11886-014-0506-3 · Cited by 6
Tryptophan probes reveal residue-specific phospholipid interactions of apolipoprotein C-III
Pfefferkorn, C. M., Walker, R. L., He, Y., Gruschus, J. M., & Lee, J. C. (2015) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2015.08.018 · Cited by 6
Zeggini, E., Gloyn, A. L., & Hansen, T. F. (2016) · Diabetologia · doi:10.1007/s00125-016-3926-3 · Cited by 6
Adrenoceptor‐related decrease in serum triglycerides is independent of PPAR α activation
Konstandi, M., Kypreos, K. E., Matsubara, T., Xepapadaki, E., Shah, Y. M., Krausz, K. W., Andriopoulou, C. E., Kofinas, A., & Gonzalez, F. J. (2019) · FEBS Journal · doi:10.1111/febs.14966 · Cited by 6
Apolipoproteins in circulation: At the interface of thrombosis and stroke initiation
Etuzé, T., Vivien, D., & Dubois, F. (2025) · Progress in Lipid Research · doi:10.1016/j.plipres.2025.101343 · Cited by 6
Unanticipated Enhancement of Intestinal TG Output by Apoc3 ASO Inhibition
Syed‐Abdul, M. M., Tian, L., & Lewis, G. F. (2023) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.123.319765 · Cited by 4
Emerging drugs for hyperlipidaemia: an update
Florentin, M., Kostapanos, M. S., Kei, A. A., & Elisaf, M. (2014) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2014.976553 · Cited by 5
Drug Therapy for Hypertriglyceridemia and Familial Chylomicronemia Syndrome: Focus on Volnesorsen
Gesner, M., & Frishman, W. H. (2022) · Cardiology in Review · doi:10.1097/crd.0000000000000468 · Cited by 5
Posicionamento Brasileiro sobre Síndrome da Quilomicronemia Familiar – 2023
Izar, M. C. D. O., Santos, R. D., Assad, M. H. V., Chagas, A. C. P., Toledo, A. D. O., Nogueira, A. C. C., Souto, A. C. C. F., Lottenberg, A. M., Chacra, A. P. M., Ferreira, C. E. D. S., et al. (2023) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20230203 · Cited by 7
Fukase, T., Dohi, T., Nishio, R., Takeuchi, M., Takahashi, N., Chikata, Y., Endo, H., Doi, S., Nishiyama, H., Okai, I., et al. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1430203 · Cited by 5
Antisense Oligonucleotides in Dyslipidemia Management: A Review of Clinical Trials
Ogieuhi, I. J., Callender, K., Odukudu, G.-D. O., Obi, E. S., Muzofa, K., Babalola, A. E., Ugiomoh, O. M.-A., Umenzeakor, K. H., Akingbola, A., Ayoson, C. O., et al. (2024) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-024-00682-w · Cited by 5
APOC3: Triglycerides do matter
Hassan, M. S. (2014) · Global Cardiology Science and Practice · doi:10.5339/gcsp.2014.38 · Cited by 5
Volta, A., Hovingh, G. K., & Grefhorst, A. (2018) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000489 · Cited by 5
Genomic Strategies Toward Identification of Novel Therapeutic Targets
Kessler, T., & Schunkert, H. (2020) · Handbook of experimental pharmacology · doi:10.1007/164_2020_360 · Cited by 5
Corbin, L. J., Hughes, D. A., Chetwynd, A. J., Taylor, A. E., Southam, A. D., Jankevics, A., Weber, R. J. M., Groom, A., Dunn, W. B., & Timpson, N. J. (2020) · Metabolomics · doi:10.1007/s11306-020-01689-9 · Cited by 5
Kastelein, J. J. P. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61332-5 · Cited by 5
Deep Apolipoprotein Proteomics to Uncover Mechanisms of Coronary Disease Risk ∗
Rader, D. J., Bajaj, A., & Khetarpal, S. A. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.11.066 · Cited by 5
Tian, C., Qiu, M., Lv, H.-Z., Yue, F., & Zhou, F.-F. (2022) · ACS Omega · doi:10.1021/acsomega.2c05663 · Cited by 4
Isotopic Tracers for the Measurement of Metabolic Flux Rates
Beysen, C., Hellerstein, M. K., & Turner, S. (2014) · Springer eBooks · doi:10.1007/978-1-4471-4920-0_3 · Cited by 4
Personalized Management of Cardiovascular Disorders
Jain, K. K. (2015) · Springer eBooks · doi:10.1007/978-1-4939-2553-7_14 · Cited by 4
Tackling Residual Atherosclerotic Risk in Statin-Treated Adults: Focus on Emerging Drugs
Takata, K., & Nicholls, S. J. (2018) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-018-0312-1 · Cited by 4
Investigational drugs in development for hypertriglyceridemia: a coming-of-age story
Rhainds, D., Brodeur, M. R., & Tardif, J. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1696772 · Cited by 4
Antisense Oligonucleotides for the Treatment of Hypertriglyceridemia and Hyperlipoproteinemia(a)
Hanßen, R., & Gouni‐Berthold, I. (2017) · Current Pharmacology Reports · doi:10.1007/s40495-017-0115-0 · Cited by 4
Metadata
- Authors
- Graham, M. J., Lee, R. G., Bell, T. A., Fu, W., Mullick, A. E., Alexander, V. J., Singleton, W., Viney, N., Geary, R., Su, J., Baker, B. F., Burkey, J., Crooke, S. T., & Crooke, R. M.
- Affiliations
- Ionis Pharmaceuticals (United States) (US)
- Corresponding author
- Graham, Mark J.
- Lee, Richard G.
- ORCID
- Venue
- Circulation Research
- Published
- 2013-05-24
- Volume
- 112
- Issue
- 11
- Pages
- 1479-1490
- ISSN
- 0009-7330 (ISSN-L)
- 1524-4571
- OpenAlex
- W2170210469
- Cited by
- 377
- References
- 71
- Citations by year
- 2026: 16 · 2025: 14 · 2024: 15 · 2023: 17 · 2022: 31 · 2021: 19 · 2020: 41 · 2019: 31 · 2018: 29 · 2017: 25 · 2016: 45 · 2015: 41 · 2014: 39 · 2013: 12
- FWCI
- 31.05
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Circulation Research (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- apolipoprotein C-III, antisense oligonucleotides, plasma triglycerides, hypertriglyceridemia, triglyceride-lowering therapy, cardiovascular risk factors, type 2 diabetes, metabolic syndrome, hepatotoxicity, non-human primates
- MeSH terms
- Animals, Double-Blind Method, Humans, Macaca fascicularis, Macaca mulatta, Mice, Inbred C57BL, Oligonucleotides, Placebos, Rats, Zucker, Receptors, LDL, Risk Factors, RNA, Messenger, Triglycerides, Hypertriglyceridemia, Genetic Therapy, Oligonucleotides, Antisense, Mice, Knockout, Mice, Rats, Apolipoprotein C-III
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
